文献速递乳腺癌

乳腺癌指数预测aTTom试验中延长内分泌治疗获益

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
PubMed 文献 · Ann Oncol · 2019-01-01

Trans-aTTom是一项多机构前瞻性-回顾性研究,在583例HR+、N+乳腺癌患者中评估BCI(HOXB13/IL17BR比值)预测延长他莫昔芬治疗获益的能力。BCI高表达患者从10年对比5年他莫昔芬治疗中显著获益(HR 0.35,95%CI 0.15-0.86,P=0.027),而BCI低表达患者无显著获益(HR 1.07,95%CI 0.69-1.65,P=0.768),交互作用显著(P=0.012)。

要点

  • BCI高表达患者延长他莫昔芬至10年显著获益,绝对风险降低10.2%。
  • BCI低表达患者延长治疗无显著获益,绝对风险降低-0.2%。
  • BCI连续水平可预测延长治疗获益幅度,而中心ER/PR状态不能。

核心结论

  • BCI高H/I表达可预测内分泌应答,识别出从10年对比5年他莫昔芬治疗中显著获益的HR+、N+患者亚组。
  • 该数据与既往MA.17数据一致,为BCI作为延长内分泌治疗获益的预测生物标志物提供了1B级证据。

研究设计与样本

  • Trans-aTTom是一项多机构、前瞻性-回顾性研究,纳入有可用FFPE原发肿瘤块的患者。
  • BCI检测及中心免疫组化ER/PR状态测定均对临床结局设盲。
  • 采用Kaplan-Meier分析和Cox回归评估生存终点,以无复发生存间期(RFI)为主要终点。
  • 采用似然比检验评估延长内分泌治疗与BCI(H/I)的交互作用。

主要发现

  • 在583例HR+、N+患者中,49%分类为BCI(H/I)高表达,从10年对比5年他莫昔芬治疗中显著获益(HR 0.35;95%CI 0.15-0.86;基于RFI的绝对风险降低10.2%;P=0.027)。
  • BCI(H/I)低表达患者从延长内分泌治疗中无显著获益(HR 1.07;95%CI 0.69-1.65;绝对风险降低-0.2%;P=0.768)。
  • 连续BCI(H/I)水平可预测延长他莫昔芬治疗的获益幅度,而中心ER和PR状态不能。
  • 延长他莫昔芬治疗与BCI(H/I)的交互作用在调整临床病理因素后具有统计学显著性(P=0.012)。

关键数值与推荐

  • BCI(H/I)高表达:延长他莫昔芬治疗HR 0.35(95%CI 0.15-0.86),绝对风险降低10.2%,P=0.027。
  • BCI(H/I)低表达:延长他莫昔芬治疗HR 1.07(95%CI 0.69-1.65),绝对风险降低-0.2%,P=0.768。
  • 延长治疗与BCI(H/I)交互作用P=0.012。

临床怎么用

  • 对于HR+、N+早期乳腺癌患者,可检测BCI(H/I)以辅助筛选可能从延长他莫昔芬治疗至10年中获益的人群。
  • BCI高表达患者可能从延长内分泌治疗中显著获益,BCI低表达患者可能不支持延长治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extending the duration of adjuvant endocrine therapy reduces the risk of recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast cancer. Validated predictive biomarkers of endocrine response could significantly improve patient selection for extended therapy. Breast cancer index (BCI) [HOXB13/IL17BR ratio (H/I)] was evaluated for its ability to predict benefit from extended endocrine therapy in patients previously randomized in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. PATIENTS AND METHODS: Trans-aTTom is a multi-institutional, prospective-retrospective study in patients with available formalin-fixed paraffin-embedded primary tumor blocks. BCI testing and central determination of estrogen receptor (ER) and progesterone receptor (PR) status by immunohistochemistry were carried out blinded to clinical outcome. Survival endpoints were evaluated using Kaplan-Meier analysis and Cox regression with recurrence-free interval (RFI) as the primary endpoint. Interaction between extended endocrine therapy and BCI (H/I) was assessed using the likelihood ratio test. RESULTS: Of 583 HR+, N+ patients analyzed, 49% classified as BCI (H/I)-High derived a significant benefit from 10 versus 5 years of tamoxifen treatment [hazard ratio (HR): 0.35; 95% confidence interval (CI) 0.15-0.86; 10.2% absolute risk reduction based on RFI, P = 0.027]. BCI (H/I)-low patients showed no significant benefit from extended endocrine therapy (HR: 1.07; 95% CI 0.69-1.65; -0.2% absolute risk reduction; P = 0.768). Continuous BCI (H/I) levels predicted the magnitude of benefit from extended tamoxifen, whereas centralized ER and PR did not. Interaction between extended tamoxifen treatment and BCI (H/I) was statistically significant (P = 0.012), adjusting for clinicopathological factors. CONCLUSION: BCI by high H/I expression was predictive of endocrine response and identified a subset of HR+, N+ patients with significant benefit from 10 versus 5 years of tamoxifen therapy. These data provide further validation, consistent with previous MA.17 data, establishing level 1B evidence for BCI as a predictive biomarker of benefit from extended endocrine therapy. TRIAL REGISTRATION: ISRCTN17222211; NCT00003678.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial. Ann Oncol. 2019. PMID: 31504126. doi:10.1093/annonc/mdz289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。